KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash & Equivalents (2016 - 2026)

Biogen has reported Cash & Equivalents over the past 18 years, most recently at $3.4 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 30.19% year-over-year to $3.4 billion; the TTM value through Mar 2026 reached $3.4 billion, up 30.19%, while the annual FY2025 figure was $3.0 billion, 26.67% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $3.4 billion at Biogen, up from $3.0 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $3.9 billion in Q3 2025 and troughed at $1.0 billion in Q4 2023.
  • A 5-year average of $2.5 billion and a median of $2.6 billion in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 69.29% in 2023 and later soared 141.84% in 2025.
  • Year by year, Cash & Equivalents stood at $3.4 billion in 2022, then crashed by 69.29% to $1.0 billion in 2023, then soared by 126.21% to $2.4 billion in 2024, then grew by 26.67% to $3.0 billion in 2025, then grew by 12.44% to $3.4 billion in 2026.
  • Business Quant data shows Cash & Equivalents for BIIB at $3.4 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.9 billion in Q3 2025.